NovaBay Pharmaceuticals (NBY) Competitors $3.73 -0.49 (-11.61%) As of 09/5/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NBY vs. AYTU, IXHL, ABP, AIMD, ATNF, LEXX, EDSA, MBRX, LSB, and CYCCShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Aytu BioPharma (AYTU), Incannex Healthcare (IXHL), Abpro (ABP), Ainos (AIMD), 180 Life Sciences (ATNF), Lexaria Bioscience (LEXX), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), LakeShore Biopharma (LSB), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. Its Competitors Aytu BioPharma Incannex Healthcare Abpro Ainos 180 Life Sciences Lexaria Bioscience Edesa Biotech Moleculin Biotech LakeShore Biopharma Cyclacel Pharmaceuticals NovaBay Pharmaceuticals (NYSE:NBY) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in NBY or AYTU? 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, NBY or AYTU? NovaBay Pharmaceuticals has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovaBay Pharmaceuticals$9.78M2.22-$9.64M-$53.72-0.07Aytu BioPharma$81M0.25-$15.84M-$0.72-3.13 Does the media prefer NBY or AYTU? In the previous week, Aytu BioPharma had 1 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 1 mentions for Aytu BioPharma and 0 mentions for NovaBay Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.50 beat NovaBay Pharmaceuticals' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Overall Sentiment NovaBay Pharmaceuticals Neutral Aytu BioPharma Positive Which has more volatility & risk, NBY or AYTU? NovaBay Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Is NBY or AYTU more profitable? Aytu BioPharma has a net margin of 2.37% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Aytu BioPharma's return on equity of 3.51% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NovaBay Pharmaceuticals-102.72% -7,293.78% -158.41% Aytu BioPharma 2.37%3.51%0.91% Do analysts prefer NBY or AYTU? NovaBay Pharmaceuticals currently has a consensus price target of $0.85, indicating a potential downside of 77.21%. Aytu BioPharma has a consensus price target of $10.00, indicating a potential upside of 344.44%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than NovaBay Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAytu BioPharma beats NovaBay Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$24.58M$863.38M$5.76B$21.40BDividend YieldN/A4.84%6.71%3.50%P/E Ratio-0.071.0975.5429.64Price / Sales2.2226.53480.4248.97Price / CashN/A19.5636.9624.54Price / Book0.886.7211.444.55Net Income-$9.64M-$4.20M$3.28B$999.70M7 Day Performance109.55%0.53%0.96%0.57%1 Month Performance531.35%12.30%7.83%5.65%1 Year Performance736.70%28.54%62.65%17.39% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals0.4585 of 5 stars$3.73-11.6%$0.85-77.2%+695.6%$24.58M$9.78M-0.0730Gap DownHigh Trading VolumeAYTUAytu BioPharma3.9247 of 5 stars$2.29-0.6%$10.00+337.4%-6.3%$20.53M$81M-3.18160Short Interest ↓IXHLIncannex Healthcare0.5483 of 5 stars$0.71-3.6%N/A-69.1%$20.45M$10K-0.573Short Interest ↓Gap DownHigh Trading VolumeABPAbproN/A$0.24-1.0%$4.00+1,548.1%N/A$19.46M$180K0.0015Gap DownAIMDAinos0.415 of 5 stars$3.99+3.9%N/A+22.5%$18.59M$20K-0.8040News CoverageAnalyst UpgradeShort Interest ↑Gap DownATNF180 Life Sciences0.3085 of 5 stars$3.08-6.8%N/A+24.1%$18.57MN/A-0.207Gap DownLEXXLexaria Bioscience2.9216 of 5 stars$0.92-12.6%$4.00+335.7%-68.8%$18.29M$615.92K-1.407Short Interest ↑Gap UpHigh Trading VolumeEDSAEdesa Biotech1.2691 of 5 stars$2.45+1.2%$5.00+104.1%-42.7%$17.25MN/A-1.8620MBRXMoleculin Biotech3.1676 of 5 stars$0.56-3.1%$4.00+618.1%-84.9%$16.87MN/A0.0020Analyst RevisionGap DownLSBLakeShore Biopharma1.478 of 5 stars$0.81-1.5%N/A-81.0%$16.78M$614.96M0.00773Positive NewsShort Interest ↓Gap DownCYCCCyclacel Pharmaceuticals1.2673 of 5 stars$7.49-0.9%N/A-97.2%$16.77M$40K-0.0114Positive NewsAnalyst DowngradeShort Interest ↓ Related Companies and Tools Related Companies AYTU Alternatives IXHL Alternatives ABP Alternatives AIMD Alternatives ATNF Alternatives LEXX Alternatives EDSA Alternatives MBRX Alternatives LSB Alternatives CYCC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NBY) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
